Gadoquatrane Patent Expiration
Gadoquatrane was first introduced by Bayer Healthcare Pharmaceuticals Inc
Gadoquatrane Patents
Given below is the list of patents protecting Gadoquatrane, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ambelvist | US11944690 | Formulation Of Contrast Media And Process Of Preparation Thereof | May 19, 2040 | Bayer Healthcare |
| Ambelvist | US12303573 | Formulation Of Contrast Media And Process Of Preparation Thereof | Nov 21, 2039 | Bayer Healthcare |
| Ambelvist | US10137209 | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging | May 30, 2036 | Bayer Healthcare |
| Ambelvist | US10722601 | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging | May 30, 2036 | Bayer Healthcare |
| Ambelvist | US11491245 | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging | May 30, 2036 | Bayer Healthcare |
| Ambelvist | US12478696 | Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging | May 30, 2036 | Bayer Healthcare |
Gadoquatrane's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gadoquatrane:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric) | Bayer | NA |
COMPLETED
(Jul 1, 2026)
| PHASE3 |
| A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) | Bayer | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |